This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.
Hereditary prostate cancer [17 genes]
Prostate cancer is a clinically and genetically heterogeneous disease with hereditary factors that are estimated to represent between 40-50% of cases, which include rare to medium high penetrance genetic variants and common low penetrance genetic variants. In particular, it has been demonstrated that HOXB13 and BRCA2 mutations increase the risk of prostate cancer. Mutations in BRCA2 would be responsible for 1-2% of early prostate tumors, conferring a higher risk of suffering prostate cancer at earlier ages (<65 years). Other syndromes associated with a higher risk of prostate cancer exist, among which Lynch syndrome stands out.
Request study
Informed consent
Steps to follow
Ask for information
Steps to follow
How to order
1. Download & fill out
Please cover as many fields as possible in both documents
2. Sample collection
Three sample types: saliva, peripheral blood or genomic DNA
3. Pack the sample
Please pack the sample in a way to prevent leakage
4. Send the sample & the request
Please schedule the delivery for Mon–Thur: 8am – 5pm
5. Result: the report
Via: Client Site HIC / Client Site Imegen / Certified email
Solicita información de
Hereditary prostate cancer
Turnaround time (TAT): 4 weeks
Ref. S-202009123
Hereditary prostate cancer: View panel
The genetic study can help carry out a correct differential diagnosis of the pathology and, therefore, not only guide the treatment but also provide a better prognosis approximation. Our recommendation includes a panel of multiple genes taking into account the different syndromes associated with both hereditary prostate cancer and hereditary renal cancer.
- ABRAXAS1
- ATM
- BRCA1
- BRCA2
- BRIP1
- CHEK2
- HOXB13
- MRE11
- MSH2
- MSH6
- NBN
- PALB2
- PMS2
- RAD51C
- RAD51D
- MLH1
- TP53
Priority Genes : Genes where there is sufficient evidence (clinical and functional) to consider them associated with the disease; they are included in the clinical practice guidelines.
Secondary Genes: Genes related to the disease, but with a lower level of evidence or that constitute sporadic cases.
* Candidate Genes: Not enough evidence in humans, but potentially associated with the disease.